News
New preclinical findings highlight Telomir-1’s ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene – often called the body’s natural “cell cycle brake.” These results ...
Telomir Pharmaceuticals (TELO) announced new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback